Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs

Siakavellas, Spyros I.; Goulis, John; Manolakopoulos, Spilios; Triantos, Christos; Gatselis, Nikolaos; Tsentemidou, E.; Kranidioti, Hariklia; Zisimopoulos, Konstantinos; Tsoulas, Christos; Dalekos, George Ν.; Papatheodoridis, George

doi:10.20524/aog.2020.0525

Cited by 6 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient compliance is defined as “the level at which the patient's behavior in the changes in medications, dietary combinations, and lifestyle habits is consistent with the doctor's order.” The word “listen” was first used by Chinese experts from Ruan to teach Chinese translation applications [ 10 ]. The emphasis on adherence refers to the level at which the patient's actions are consistent with the scripting written by the doctor in advance in the treatment and prevention of the disease.…”

Section: State-of-the-art Technologymentioning

confidence: 99%

The Application of Focused Care Model in the Management of Hepatitis B Patients in a Tertiary Care Hospital and the Impact on Patients’ Quality of Life

Zhang

Wang

Shan

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Chronic hepatitis B is one of the common infectious diseases in the world, with a wide epidemic range and strong contagiousness, which is difficult to completely eradicate. From July 2020 to April 2022, 142 patients with hepatitis B who were admitted to tertiary hospitals were selected and randomly divided into 2 cases, with 71 cases per case. The control group adopts a conventional model, and the observation group implements a nursing model based on the control group. The management capacity and quality of life before and after the two groups of care were compared. 94 patients with chronic hepatitis B who were admitted to the hospital from July 2020 to April 2022 were selected, and 47 cases were divided into the control group and observation group according to the admission time. The control group is given a conventional model, and the observation group is given a nursing model on the basis of the control group. Both groups of patients observed anxiety self-assessment scale (SAS), depression self-assessment scale (SDS), short life span scale (SF-36) scores, and treatment conditions before and after the intervention, to explore the application of nursing model in the management of hepatitis B patients in tertiary hospitals and its impact on patient quality of life. Based on study’s precare outcomes, there was no statistically significant difference between the self-administered scale (PIH) score and the quality of life measurement summary scale (QOL-BREF) score ( P > 0.05 ) between the two groups. After one month of care, both groups had lower PIH scores than before care, and QOL-BREF scores were higher than before care ( P < 0.05 ). After one month of treatment, the PIH score of the observation group was significantly reduced, and the QOL-BREF score after one month of treatment was significantly higher than that of the control group ( P < 0.05 ). The SAS and SDS scores in the observation group were lower than those in the control group, and the quality of life scores and treatment compliance were higher than those in the control group, and the difference was statistically significant ( P < 0.05 ). Conclusions. The nursing model can effectively improve the management and quality of life of hepatitis B patients. It also had a significant positive effect on the therapeutic capacity and quality of life of patients with hepatitis B and improved patient compliance behavior and quality of life.

show abstract

Section: State-of-the-art Technologymentioning

confidence: 99%

The Application of Focused Care Model in the Management of Hepatitis B Patients in a Tertiary Care Hospital and the Impact on Patients’ Quality of Life

Zhang

Wang

Shan

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Antiviral treatment was the key to the treatment of patients with CHB, which could improve the quality of life of patients and prolong the survival time. Nucleos(t)ide analog (NA) drugs were important antiviral therapy drugs for patients with CHB ( 48 ). But only 11% of 30 million patients with CHB received standardized antiviral treatment in China ( 31 ) for poor medicines affordability.…”

Section: Introductionmentioning

confidence: 99%

“…The massive price cuts dramatically impacted overall drug expenditures. The NA represents the treatment option for the majority of patients with CHB ( 48 ), such as Entecavir, Tenofovir Fumarate, Lamivudine, Adefovir dipivoxil, and Telbivudine. Entecavir and Tenofovir Fumarate are guanine NAs for the treatment of HIV infection, which were equally recommended by the Guidelines as the first-line antiviral treatments for CHB at present ( 51 ).…”

Section: Introductionmentioning

confidence: 99%

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis

Wen

Yin

Cui

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Objectives: To assess the effects of the National Centralized Drug Purchasing Pilot Program on nucleos(t)ide analogs (NAs) in Shenzhen city.Methods: Drugs procurement records in medical institutions were analyzed covering the period from January 2018 to December 2019. An interrupted time series (ITS) analysis was used to evaluate the impact of the “4+7” pilot policy on NAs in Shenzhen city. The outcome measures were usage volume, expenditures, daily cost, and distribution structure of NAs.Findings: After the introduction of the “4+7” pilot policy, the defined daily doses (DDDs) of NA drugs increased by 76.48%, the expenditures and defined daily dose cost (DDDc) of NAs decreased by 45.43 and 69.08%, respectively. The proportion of winning products in Entecavir and Tenofovir Fumarate DDDs was increased by 64.21 and 19.20%, respectively. The post-intervention period witnessed a significant increase in the regression level for NAs DDDs (level coefficient: β2 = 631.87, p < 0.05). The expenditures (trend coefficient: β3 = 392.24, p < 0.05) and DDDc (level coefficient: β2 = −6.17, p < 0.001; trend coefficient: β3 = −0.21, p < 0.05) of NAs showed decreasing trend in the post-intervention period. The expenditures of original products and generic products both showed a decreasing trend in the post-intervention period (trend coefficient: β3 = −372.78, p < 0.05, trend coefficient: β3 = −130.78, p < 0.05, respectively). The DDDc of original products in the policy-related varieties was a significant decrease in the regression slope and level (level coefficient: β2 = −2.18, p < 0.05; trend coefficient: β3 = −0.32, p < 0.01).Conclusion: After the implementation of the“4+7” policy, the DDDc of NAs decreased, the accessibility of policy-related drugs was improved, and the usage of generic medicine was promoted.

show abstract

“…3,4 Antiviral therapy, especially with the first-line nucleos(t)ide analogs (NAs), 5 is the key to reducing HBV-related serious consequences, such as cirrhosis and hepatocellular carcinoma. 6,7 However, the treatment rate and utilization of the preferred antiviral agents have been low largely due to the high cost of the first-line therapy in China. 8 To improve the accessibility and affordability of medicines, the General Office of the State Council of the People's Republic of China issued the National Centralized Drug Procurement (NCDP) policy in January 2019.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China

Zhao¹,

Li²,

Wang³

et al. 2022

J Clin Transl Hepatol

View full text Add to dashboard Cite

Background and Aims:The National Centralized Drug Procurement (NCDP) policy was launched in mainland China in April 2019, with entecavir (ETV) and tenofovir disoproxil fumarate (TDF) being included in the procurement list. We conducted the current study to investigate the impact of the NCDP policy on the utilization and expenditures of antiviral therapy for chronic hepatitis B (CHB) in China. Methods: Procurement records, including monthly purchase volume, expenditure, and price of nucleos(t)ide analogs (NAs), were derived from the National Healthcare Security Administration from April 2018 to March 2021. The changes in volumes and expenditures of the first-line NAs and bid-winning products were calculated. The effects of price, volume, and structure related to drug expenditure were calculated by the Addis and Magrini (AM) Index System Analysis. Results: The purchase volume of NAs significantly increased from 134.3 to 318.3 million DDDs, whereas the expenditure sharply decreased from 1,623.41 to 490.43 million renminbi (RMB) or 241.94 to 73.09 million US dollars (USD). The proportions of firstline NAs rose from 72.51% (ETV: 69.00%, TDF: 3.51%) to 94.97% (ETV: 77.42%, TDF: 17.55%). AM analysis showed that the NCDP policy decreased the expenditure of all NAs (S=0.91) but increased that of the first-line NAs in the bidwinning list (S=1.13). Assuming the population size of CHB patients remains stable and a compliance rate of ≥75%, the proportion of CHB patients receiving first-line antiviral therapy would increase from 6.36-8.48% to 11.56-15.41%. Conclusions:The implementation of the NCDP policy significantly increased the utilization of first-line NAs for CHB patients at a lower expenditure. The findings provided evidence for optimizing antiviral therapy strategy and allocating medical resources in China.

show abstract

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs

Cited by 6 publications

References 24 publications

The Application of Focused Care Model in the Management of Hepatitis B Patients in a Tertiary Care Hospital and the Impact on Patients’ Quality of Life

The Application of Focused Care Model in the Management of Hepatitis B Patients in a Tertiary Care Hospital and the Impact on Patients’ Quality of Life

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China

Contact Info

Product

Resources

About